Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.41 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12427348 | 0.92 | KCNH2 (0.51) | ALDH1A1POLBOPRM1NPSR1KCNH2 | |
| SCHEMBL12427407 | 0.90 | ALDH1A1 (0.53) | ALDH1A1POLBCHRM2CHRM1OPRM1 | |
| SCHEMBL12427340 | 0.87 | KCNH2 (0.49) | ALDH1A1POLBOPRM1NPSR1KCNH2 | |
| SCHEMBL1006767 | 0.86 | ALDH1A1 (0.48) | ALDH1A1POLBCHRM2CHRM1OPRM1 | |
| SCHEMBL12427325 | 0.86 | ALDH1A1 (0.56) | ALDH1A1POLB | |
| SCHEMBL1972816 | 0.85 | ALDH1A1 (0.45) | ALDH1A1POLBCHRM2CHRM1OPRM1 | |
| SCHEMBL1973757 | 0.85 | ALDH1A1 (0.46) | ALDH1A1POLBCHRM2CHRM1OPRM1 | |
| SCHEMBL12427322 | 0.85 | KCNH2 (0.43) | ALDH1A1POLBOPRM1NPSR1KCNH2 | |
| SCHEMBL12427409 | 0.84 | KCNH2 (0.55) | ALDH1A1POLBOPRM1NPSR1KCNH2 | |
| SCHEMBL12917487 | 0.83 | ALDH1A1 (0.47) | ALDH1A1POLBCHRM2CHRM1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977349-B2 | Substituted quinolones III | AICURIS GMBH & CO. KG (DE) | 2011-07-12 | — | — | US | disclosed |
| US-7977349-B2 | Substituted quinolones III | AICURIS GMBH & CO. KG (DE) | 2011-07-12 | — | — | US | disclosed |
| US-20090181996-A1 | SUBSTITUTED QUINOLONES III | BAYER HEALTHCARE AG (DE) | 2009-07-16 | — | — | US | disclosed |
| US-20090181996-A1 | SUBSTITUTED QUINOLONES III | BAYER HEALTHCARE AG (DE) | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181996-A1 | SUBSTITUTED QUINOLONES III | IRF3, TPMT, TOP2A | ALDH1A1 3228/4885POLB 77/4885CHRM2 3219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.